Clinolipid (lipid injectable emulsion)
Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER)
July 2016
ADVERSE REACTIONS
Post-marketing Experience
Immune System Disorders: Hypersensitivity with the manifestations of rash...
Source: Drugs.com - Labeling Changes - Category: Drugs & Pharmacology Source Type: alerts
More News: Drugs & Pharmacology | Marketing